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The BNIP-2 and Cdc42GAP Homology (BCH) domains constitute a new and expanding family of
highly conserved scaffold protein domains that regulate Rho, Ras and MAPK signaling, leading to
cell growth, apoptosis, morphogenesis, migration and differentiation. Such versatility is achieved
via their ability to target small GTPases and their immediate regulators such as GTPase-activating
proteins (GAPs) and guanine nucleotide exchange factors (GEFs), their ability to form intra-
molecular or inter-molecular interaction with itself or with other BCH domains, and also by their
ability to bind diverse cellular proteins such as membrane receptors, isomerase, caspases and
metabolic enzymes such as glutaminase. The presence of BCH and BCH-like domains in various
proteins and their divergence from the ancestral lipid-binding CRAL–TRIO domain warrant the need
to examine closely their structural, functional and regulatory plasticity in isolation or in concert
with other protein modules present in the same proteins.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
1.1. Modular protein domains deﬁnes speciﬁcity, integration and
crosstalk of signaling networks
Protein domains are the autonomous, minimal modular entities
that constitute the basic structural or/and functional units of a
polypeptide. They can act as protein docking sites, enzymatic units
or regulatory devices and are classiﬁed into different families
according to their conserved primary sequences. Each family of do-
main recognizes unique interaction motif at their target sites. As
such, proteins exploit different architecture designs of modular do-
mains in order to exert common, overlapping or distinct functions,
particularly in mediating protein–protein and protein–lipid inter-
actions that form the basis for intracellular and intercellular signal-
ing [1].
As cells sense both biochemical and physical environments, it is
important to deﬁne how these domains work in isolation and inal Societies. Published by Elsevier
opmental Biology Laboratory,
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72 6123.combination, and how their potential functions are regulated
across molecular, cellular and tissue levels. For example, the
adaptor protein, Grb2 contains both Src-homology-2 (SH2) and
Src-homology-3 (SH3) domains which bridge interaction between
the phosphorylated tyrosine residue on the receptor tyrosine
kinase and the core PXXP motif of the RasGEF, SOS, respectively,
thereby transducing signals upon binding of ligands at the extra-
cellular space to intracellular milieu [2]. Precise molecular recogni-
tion is also important for transcriptional regulation. For example,
under the HIPPO signaling which is crucial for the control of organ
size and tumor suppression, the LATS kinase via its PPxY motif,
targets the WW domain of the transcriptional regulator, Yes
associated protein (YAP) to phosphorylate YAP, leading to seques-
tration of YAP in cytoplasm by protein 14-3-3. This mechanism
helps reduce the YAP-induced cell proliferation and tumor
suppression [3]. Similarly, in protein trafﬁcking and targeting,
interaction between the pleckstrin homology (PH) domain of the
molecular motor, dynamin and phosphoinositide is essential for
endocytosis [4,5].
To further enhance the efﬁciency of multi-component signaling
networks, cells employ speciﬁc scaffold proteins that utilize their
multiple protein domains to recruit and organize different targets
into higher order macromolecular complexes at speciﬁc locationB.V. Open access under CC BY-NC-ND license. 
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ples, the activity of Raf-Mek-Erk or Mek-Erk nodes downstream of
Ras is supported by different scaffold proteins at different locales,
namely the KSR (cell membrane), MP1 (late endosome), Sef (Golgi),
paxillin (focal adhesions), IQGAP1 (cytoskeleton) and b-arrestin
(early endosome) [6]. Such distribution of signaling nodes by
distinct hubs ensure localized and more speciﬁc control in the acti-
vation (and deactivation) of Erk during different cellular processes.
Last but not least, coordination of cell adhesion dynamics require
the FERM (four-point-one, ezrin, radizin, moesin) domain of
FAK (focal adhesion kinase) interacting with phospholipids
PtdIns(4,5)P2 at the cell membrane to release the autoinhibition
in FAK. This facilitates the recruitment of Src tyrosine kinase and
formation of focal adhesion complex via integration of many more
scaffold proteins, kinases, phosphatases, GTPases and their
immediate regulators [7,8].
Therefore, precise locales and timing for the molecular recogni-
tion by different combinations of protein domains in cis and in
trans will help deﬁne the speciﬁcity, connectivity, crosstalk and
feedback among various signaling nodes. Acting in concert, they
regulate important functions such as cytoskeleton rearrangement,
cell–cell adhesion, cell–matrix interaction, protein trafﬁcking,
organelle and membrane dynamics, cell metabolism and immune
response, gene expression and protein synthesis and stability, lead-
ing ultimately to cell growth, cell death, cell differentiation, cell
migration and invasion.
2. BCH domain as an emerging regulatory scaffold domain
2.1. Discovery of the prototypical BCH domain from BNIP-2: from
receptor tyrosine kinase to small GTPase, MAP kinase and beyond
To understand the fundamental mechanism in cell signaling it is
important to identify what and how one particular signaling pro-
tein forms its protein interaction networks and how this process
is regulated in vitro and in vivo. In our effort to decipher how acti-
vation of the ﬁbroblast growth factor receptor (FGFR) tyrosine ki-
nase could lead to novel signaling pathway, yeast 2-hybrid was
employed and BNIP-2 was identiﬁed as a candidate partner for
the cytoplasmic tail of the receptor [9]. Interestingly, only the ki-
nase-dead mutants of the FGFR could ‘‘trap’’ and co-immunopre-
cipitate with BNIP-2, indicating that their interaction was very
transient and BNIP-2 was likely to be a substrate of the receptor.
Further in vitro kinase assays and detection with phosphotyrosine
antibody conﬁrm BNIP-2 as a bone ﬁde substrate of the FGFR both
in vitro and inside the cells [9].
BNIP-2 was ﬁrst identiﬁed as one of the three interacting part-
ners for the anti-apoptotic Bcl2 and viral E1B 19 kDa protein, hence
named Bcl-2 and Nineteen kilodalton-Interacting Protein-2, BNIP-2
[10]. However, its precise biological functions remained unknown
then. Our further sequence analyses revealed 61% similarity be-
tween the C-terminus of BNIP-2 with the N-terminus, non-cata-
lytic region of Cdc42GAP (p50RhoGAP or ARHGAP1) and named
the region BNIP-2 and Cdc42GAP Homology (BCH) domain
(Fig. 1; [9,11,12]). As this domain is associated with the Rho
GTPase-activating domain (GAP) domain of Cdc42GAP, we specu-
lated that it could be linked to function and regulation of GTPases
signaling. Among key molecular switches, Ras and Rho small GTP-
ases control cell signaling and cytoskeleton networks by cycling
between their inactive GDP-bound form and active GTP-bound
state [13]. This process is tightly regulated by their guanine nucle-
otide exchange factors (GEFs) that catalyze the exchange of GDP
for GTP [14] or by their GTPase-activating proteins (GAPs) that help
hydrolyze the GTP to GDP [15]. Although the biochemical functions
of GTPases, GEFs and GAPs are well established and their deregula-tion often lead to developmental defects and disease, less is known
about how this ‘‘3G’’ (GTPase, GEF, GAP)-signalome itself is regu-
lated by cellular factors and how their functions and regulation
are linked to other signaling networks downstream of membrane
receptor and MAP kinase modules. We therefore hypothesized that
BCH domain in BNIP-2 and Cdc42GAP could serve as a binding
platform for GTPases and possibly their immediate regulators, or
they could form multimeric form of BNIP-2, as sometimes seen
for other homologous domains used in protein dimerization/
oligomerization.
Based on structural modeling, site-directed mutagenesis,
binding studies and GTPase assays, we revealed that BCH do-
main of BNIP-2 indeed binds to itself and the homologous BCH
domain of Cdc42GAP via a unique motif, 217-RRKMP-221 [11].
Interestingly, BNIP-2 BCH domain also binds Cdc42, a partner
of the Cdc42GAP, via a sequence motif similar to the CRIB
(Cdc42/Rac1-Interactive Binding) motif commonly present in
the effector proteins of Cdc42/Rac1 [16,17] (see Fig. 3A and C
for details later). Unlike binding of CRIB motif which is abso-
lutely GTP-dependent (in order to allow activation of effectors
pathway), the BCH domain of BNIP-2 does not distinguish be-
tween the unloaded, GDP and GTP-bound form of Cdc42
in vitro [9]. However, it binds preferentially to the dominant
negative form of Cdc42, T17N but not with the constitutively ac-
tive form, G12V [12]. Subsequently, we showed that these pro-
ﬁles are also observed in binding of Rho by the other
homologous BCH domains of BNIP-S [33], BNIP-XL [18] and
Cdc42GAP [19] and are distinct from that conferred by the
GTPase-binding domains of GEFs and GAPs [14,15,20]. Further-
more, BNIP-2 appeared to promote the inactivation of Cdc42
by stimulating the apparent GTPase activity of Cdc42 in vitro
and such effect is abrogated upon binding by FGFR [9] or nega-
tively regulated by the homophilic interaction of BNIP-2 or its
heterophilic interaction with Cdc42GAP [11]. Since then, by
using yeast 2-hybrid, proteomics-based mass spectrometry and
candidate approaches, we and others have expanded the family
of BNIP-2 interactomes. We have further delineated how some
of these BCH domains could in fact either activate or inactivate
speciﬁc Rho GTPases signaling depending on various cellular
contexts the proteins are present, and they could directly or
indirectly control multiple signaling and metabolic pathways.
These processes involve speciﬁc members and conformation of
Rho and Ras family of small GTPases and selective GEFs and
GAPs, growth promoting FGF receptor tyrosine kinase, myogenic
Cdo receptor and the associated JLP/p38-MAP kinase, Mek2,
microtubule-based kinesin motor, anti-apoptotic Bcl2, peptidyl
prolyl-isomerase Pin1 and glutaminase, a metabolic enzyme
essential for cell growth and neuronal differentiation (Fig. 1).
Moreover, BCH domains can undergo auto-inhibitory intra-
molecular interaction and form oligomer with identical BCH do-
mains (homophilic interaction) or with other homologous BCH
domains (heterophilic interaction). They also collaborate with
other protein modules and their interactomes on the same pro-
teins (in cis) or with different proteins (in trans) in order to en-
sure faithful signaling integration and crosstalk. The basis for
such plasticity for BNIP-2 and several BCH-containing proteins
will be further highlighted and discussed below in the context
of their versatile binding capabilities through their multiple
binding motifs, their dynamic disposition within the cells, their
synergism (or antagonism) with other protein domains in cis or
in trans, their potential regulation by transcription, alternative
transcription start sites, alternative RNA splicing and post-trans-
lational modiﬁcations, and their molecular evolution which could
shed further lights on the common and divergent properties of
BCH domains with other protein modules.
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Fig. 1. The BCH domain and its expanding protein interaction networks. Regions in blue depict the conserved domains between the C-terminus of BNIP-2 and the N-terminus
of Cdc42GAP, hence named BNIP-2 and Cdc42GAP Homology (BCH) domain. This novel protein module which is present in diverse proteins can interact with Rho and Ras
small GTPases, their GEFs and GAPs, membrane receptors, glutaminase, Pin1, E1B-19 kDa protein, Bcl2 and other cellular proteins where they regulate diverse signaling
pathways, leading to changes in cell morphology, motility, differentiation, protein trafﬁcking and apoptosis. BCH domain can also interact with itself (homophilic) or with
other homologous BCH domains (heterophilic). For clarity, proteins that bind outside the BCH domains (heterophilic) are not shown here although they could co-regulate
speciﬁc processes with the interactome of BCH domains.
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2.2.1. BCH domain deﬁnes a distinct functional subclass of the CRAL/
TRIO superfamily
Although initially identiﬁed as a region of high protein se-
quence homology between BNIP-2 and Cdc42GAP, BCH domain
also shares 14% sequence identity with the CRAL_TRIO domain,
the lipophilic domain of the Saccharomyces cerevisiae Sec14p pro-
tein, suggesting that both domains could have evolved from a com-
mon ancestral sequence. CRAL_TRIO domain was ﬁrst identiﬁed in
cellular retinaldehyde binding protein (CRALBP) and Trio (a RhoG-
EF) [21]. Other proteins such as tyrosine phosphatase [22], a-
tocopherol transfer protein [23], RasGAP neuroﬁbromatosis type-
1 protein (NF1) and several other RhoGEFs such as Dbl, Duo, Dbs,
Kalirin [24], all are thought to possess similar protein domains.
However, each member binds diverse small hydrophobic ligands.
For examples, the CRAL_TRIO domain of Sec14L group binds phos-
photidylinositol, aTTP has afﬁnity for tocopherol and CRALBP binds
retinaldehyde [25]. The ligand speciﬁcities of the RhoGEFs and Ras-
GAP groups (represented by NF1 proteins) is currently unknown.
However, unlike the BCH domains, none of the CRAL–TRIO do-
mains is known to be associated with any speciﬁc protein–protein
interaction. Likewise, BCH domains are not known to interact with
any lipid molecules inside the cells. This observation raises several
important questions. How do BCH domains evolve and attain such
versatile functions? Do BCH and CRAL–TRIO domains still share
some of their ancient features and exhibit lipids binding and pro-
tein–protein interaction capabilities?
We have recently conducted extensive genome-wide, cross-
species analyses with 100 CRAL_TRIO and similar domains,
including the putative BCH sequences, from eight representative
species and compared the pattern of their sequence conservation,
gene structure, including the exon/intron evolution, and examined
the possible structural folds of BCH domain based on computa-
tional modeling [26]. The results reveal a clear distinction of BCH
domains as a novel subclass within the CRAL_TRIO superfamily
and highlight several unique differences between the two. To date,
BCH domains have been identiﬁed in at least 175 distinctive pro-
teins from the slime molds, plants, yeasts, insects, ﬁsh to human,adding to its evolutionary importance and diverse functionality
[26]. BCH domain is completely absent in prokaryotes and the
most primitive BCH domain can be identiﬁed from slime mold
(Dictyostelium), coanoﬂagellate (Monosiga), alveolates (Plasmo-
dium, Cryptosporidium), green alga (Chlamydomonas) and yeast.
Similarly, CRAL_TRIO domains are identiﬁed in many lower species
of alveolates. This indicates that BCH domains evolved from their
ancestors more than 1500 Mya ago with the appearance of Protists
[26,27].
These BCH-containing proteins can be divided into three un-
ique subgroups, namely those associated with BNIP-2 type se-
quence (Group I), with macro-domain (Group II) and with
RhoGAP protein domains (Group III) (Fig. 2). And most signiﬁ-
cantly, all these BCH domains contain a hallmark signature motif
R(R/K)h(R/K)(R/K)NL(R/K)xhhhhHPs, where ‘h’ refers to any large
and hydrophobic residue and ‘s’ is small and weakly polar resi-
due; Ala, Thr, Gly, Ser. This motif is absent from any of the
CRAL–TRIO domains, including those from Trio and NF1. Trio
and NF1 are two members of the CRAL–TRIO group that are most
closely related to the BCH domains (Figs. 2 and 3A and B). Further
analyses of the gene-structure and protein domain context indi-
cate that BCH domain-containing genes have evolved through
gene duplication, intron insertions and domain swapping events
and this divergence could have occurred as early as the appear-
ance of protists during evolution. Interestingly, sequences coding
for BCH domains can undergo alternative RNA splicing, leading to
splicing variants of BNIP-2, BNIP-2-Similar [28] and BNIP-2 Extra
Long [18] from the Group I. At least 4 splicing variants are also
identiﬁed in BCH domain-containing, proline-rich RhoGAP
protein, BPGAP [29] from the Group III. Interestingly, conservation
of certain alternatively spliced sequence such as
‘‘YEEEKFKKRQKR’’ in BNIP-2b appears to be highly similar to a se-
quence present in BNIP-2 Homology (BNIP-H, or Caytaxin; [30,31]
and this sequence is somewhat less similar to that of the corre-
sponding region in BNIP-XLa (Fig. 2). Interestingly, in addition
to alternative RNA splicing, different transcriptional initiation
sites are also used by the gene locus BMCC1/PRUNE2 to encode
three more extended isoforms of BNIP-XL (see details later). All
these dynamic features are likely to confer different properties
Fig. 2. Domain architecture and classiﬁcations of BCH domain-containing proteins. Domain architecture for the Group I, Group II and Group III type BCH-containing proteins
as deﬁned by the presence of single-BCH, or BCH domain that is associated with the macro and RhoGAP domains, respectively. The percentages indicate the extents of amino
acid sequence identities compared to the prototypical BNIP-2 BCH domain. Together, they deﬁne a distinct subclass of proteins that could have evolved from a common
ancestral module shared with primarily lipid-binding CRAL–TRIO protein domain. Shown also are amino acid sequence inserts within the BCH domains that arise from their
alternative RNA splicing. Only some of the splicing variants are represented here.
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enriching for the functional plasticity among the BCH domains.
Further sequence analyses also revealed signiﬁcant conserva-
tion in two GTPase-binding motifs, that are similar to the Rho-
binding domain (RBD) and the Cdc42/Rac interactive binding
(CRIB) domain commonly found in effector proteins of Rho andCdc42/Rac1, respectively (Fig. 3A, C and D). Among various BCH
domains, the BCH domain of BNIP-2 has been validated to contain
a novel Cdc42-binding motif (285-VPMEYVGI-292) within its CRIB-
like region ([32]; Fig. 3C). Likewise, the RBD-like motifs in BNIP-S
[33], BNIP-XL [18] and Cdc42GAP [19] have also been experimen-
tally validated (Fig. 3D). Indeed, these GTPase-binding motifs play
Fig. 3. Multiple sequence alignment and phylogenetic relationship among BCH domains. (A) Multiple sequence alignment of various BCH domains from Homo sapiens BNIP-
2a (NP_004321), BNIP-XLa (AY439213), BNIP-H (AAO63019), BNIP-Sa (AY078983), BPGAP1 (AF544240), Cdc42GAP/p50RhoGAP (Q07960), GDAP2 (CAI22738), TRIO
(AAC34245), NF1 (P21359) and Saccharomyces cerevisiae Sec14p lipid-binding domain (P24280) were generated using ClustalW (http://www.ebi.ac.uk/Tools/services/web/
toolform.ebi?tool=clustalw2) and displayed by BOXSHADE. (B) Phylogenetic tree of the BCH domains from Homo sapiens BNIP-2a (NP_004321), BNIP-XLa (AY439213), BNIP-
H (AAO63019), BNIP-Sa(AY078983), BPGAP1 (AF544240), Cdc42GAP/p50RhoGAP (Q07960), GDAP2 (CAI22738), TRIO (AAC34245), NF1 (P21359) and Saccharomyces
cerevisiae Sec14p lipid-binding domain (P24280), were generated using ClustalW as above. (C, D) Multiple sequence alignment of BCH domains from Homo sapiens BNIP-2a
(NP_004321), BNIP-XLa (AY439213), BNIP-H (AAO63019), BNIP-Sa (AY078983), BPGAP1 (AF544240), Cdc42GAP/p50RhoGAP (Q07960), GDAP2 (CAI22738), TRIO (AAC34245)
with the CRIB motif (C) of Homo sapiens PAK1 (AAH50377), Saccharomyces cerevisiae STE20 (Q03497), Candida albican (CLA4 AAAB68613) or with the RBD (Rho-binding
domain) motif (D) of Rhophilin-1 (NP_443156), PRK1/PKN (NP_002732) and Rhotekin (AAH17727). The requirement for the CRIB-like motif of BNIP-2 (highlighted in green
box in Figure A), RBD-like motifs of BNIP-XL, BNIP-Sa and Cdc42GAP (highlighted in red box in Figure A) and the BCH-BCH binding motifs of BNIP-2 and BNIP-S (highlighted in
brown box in Figure A) had been validated by experiments [18,19,32,33]. A cryptic motif ‘‘285-VPMEYVGI-292’’ that is critical for binding to Cdc42, is also shown in red box in
Figures A and C. All sequence alignments described above were generated using the default setting with protein weight matrix Gonnet, gap open 10, gap extension 0.2, gap
distance 5, iteration none and with NJ clustering.
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and cell differentiation, as will be discussed in details next. Inter-
estingly, although all BCH domains confer BCH/BCH homophilic
and heterophilic interactions, it appears that different sets of mo-
tifs are employed for different groups. For example, the motif
‘‘RRKMP’’ used on BNIP-2 [11] is only conserved in BNIP-H and
BNIP-XL, but it is absent from BNIP-S, Cdc42GAP and BPGAP1
(Fig. 3A). Indeed, mutating the corresponding region in Cdc42GAP
failed to disrupt its ability to form homophilic and heterophilic
complex [11]. BNIP-S, on the other hand, utilizes a separate motif
215-ATWYVKA-221 for its homophilic interaction (Fig. 3A)
whereas it binds to Cdc42GAP at a unique GAP-Binding Motif (aa
133–147) that overlaps with the Rho-binding region within an ex-
tended RBD-like motif (aa 133–177) [33]. Taken together, BCH do-
mains have evolved to acquire multiple functional motifs that
contribute to its functional versatility.
2.2.2. The BNIP-2 and BPGAP family proteins and their interactomes –
mechanisms of action and regulation
To further explore the extents of distribution, function and reg-
ulation of BCH domain-containing proteins, several novel se-
quences encoding multiple homologs of BNIP-2 were identiﬁed
from human and other species and their biochemical and cellular
functions delineated. In the following sections, we will highlight
how BNIP-2, BNIP-S, BNIP-XL, BNIP-H, BPGAP1 and Cdc42GAP em-
ploy their unique functional motifs in their BCH domains to engage
multiple targets and how they act in concert with other protein do-
mains to give rise to emerging functions and properties (Table 1
and Fig. 4). For examples, in the context of 3G-signalome, the
BCH domain of BNIP-2 induces cell protrusions by activating
Cdc42 via a yet unidentiﬁed regulator [32] or acting as a scaffold
for the activation of Cdc42 that promotes muscle differentiation
upon coupling to the active myogenic Cdo receptor and p38-MAPK
activation [34] (Fig. 4A); whereas the BCH domain of Cdc42GAPsequesters RhoA from inactivation by the adjacent GAP domain,
thus preventing cell rounding and retraction [19] (Fig. 4E). In con-
trast, the BCH domain of BNIP-Sa promotes cell rounding and
apoptosis by activating RhoA while simultaneously preventing
RhoA from inactivation by Cdc42GAP by forming a heterophilic
BCH/BCH complex [33] (Fig. 4D). In comparison, the BCH domain
of BNIP-XL inhibits cell transformation by sequestering oncogenic
Lbc RhoGEF from activating RhoA [18] (Fig. 4C). Extending this,
the BCH domain of the brain-speciﬁc BNIP-H/Caytaxin promotes
neurites outgrowth by acting in concert with the other non-BCH
entity as a scaffold to trafﬁc glutaminase on a kinesin motor and
towards the tip of differentiating neurons [30,35] (unpublished
data) (Fig. 4B). Last, but not least, the BCH domain of BPGAP1, a
homolog of Cdc42GAP, promotes ERK activation and cell migration
by collaborating with the RhoGAP domain and its proline-rich mo-
tifs that interact with cortactin [36], endophilin-2 [37], Mek2 and
Pin1 isomerase [38] (Fig. 4F). The mechanistic action and the pos-
sible regulation for these versatile processes are further discussed
below.
2.2.2.1. BNIP-2 with morphogenesis, cell growth, apoptosis and
differentiation. Since the earlier work that described BNIP-2 as a
partner for the pro-survival Bcl2 and E1B 19 kDa [10], we and oth-
ers have delineated the biochemical and cellular functions of BNIP-
2 as a core regulatory protein in multiple signaling gateways,
including the FGF receptor tyrosine kinase [9], Cdo receptor [34],
Cdc42 [9,12,32], Cdc42GAP [9,11,32] which all engage its BCH do-
mains (Fig. 5A). In particular, expression of BNIP-2 in epithelial and
ﬁbroblast cells induce extensive changes in cell morphology and
membrane protrusions by targeting and activating Cdc42 with its
unique Cdc42-binding motif 285-VVMEYVGI-292 present within
the core CRIB-like motif of the BCH domain ([32]; Fig. 5A). An adja-
cent region to this motif is also required for the concerted activa-
tion, but the target protein, believed to be a GEF that help
Table 1
BCH domain as a multifunctional regulatory scaffold domain. BCH domain-containing proteins regulate diverse signaling pathways and functions by utilizing their conserved BCH
domains and their interplay with other associated domains.
Proteins Target proteins Functions Regulation
BNIP-2 family
BNIP-2 (Bcl2 and 19 kDa
interacting protein-2)
Targets of BCH domain: E1B 19 kDa
and Bcl2 [10]; Cdc42 [11,12,32],
BNIP-2 [11] and Cdc42GAP
(p50RhoGAP) [11], Cdo receptor [34];
FGF receptor-1 [9]; Rho and RhoGEF
(unpublished data)
Targets of other domain: caspases
[41], granzyme B [42]
(1) Binding to viral E1B 19 kDa protein
and Bcl2 promotes cell survival [10]
(2) Substrate of FGFR [9]. Its C-terminus
shares high sequence homology with
the N-terminus of Cdc42GAP, hence
termed BCH domain [11]
(3) BCH domain binds Cdc42 via a CRIB-
like motif and leads to drastic cell
elongation and membrane protrusions
where it is localized to [32]. It also
forms BCH/BCH complex with itself
or Cdc42GAP via a different motif [11]
(4) Promotes myogenic and neuronal dif-
ferentiation by acting as a scaffold that
links Cdo receptor to activation of
Cdc42, leading to JLP-scaffolded acti-
vation of p38a/b [34,40]
(5) Human BNIP-2 is cleaved by caspases
3, 6, 8, 10 in vitro, or by caspases 3, 8
and 9 in cells [41]
(6) Also subjected to cleavage by gran-
zyme B [42]
(7) Contains a putative kinesin-binding
motif for intracellular trafﬁcking; pos-
sibly acting as scaffold for cargo traf-
ﬁcking [35]
(8) Retards MDCK epithelia cell spreading
and collective cell migration by activa-
tion of Rho (unpublished data)
(9) Binding to BPGAP1 enhances its GAP
activity towards Rho and reducing cell
proliferation (unpublished data)
(1) Homophilic or heterophilic interac-
tions via BCH domains affects Cdc42
activity [11]
(2) Phosphorylation by FGFR disrupts its
binding to Cdc42 and Cdc42GAP [9]
(3) Estrogen treatment reduces BNIP-2
expression and its pro-apoptotic
activity [43]
(4) Cleavage by caspases and granzyme B
might lead to the release of pro-apop-
totic BCH-containing fragment [41,42]
(5) Splicing within BCH domains gener-
ates BNIP-2a and BNIP-2bwith poten-
tially different properties and
functions
(6) Contextual signaling: versatility in
engaging different Rho GTPases and
their GAPs or GEFs, leading to con-
text-dependent regulation of GTPase
signaling
BNIP-H (BNIP-2 Homology;
CAYTAXIN)
Targets of BCH domain: glutaminase
KGA [30], peptidyl–prolyl isomerase
Pin1 [55]
Targets of other domain: kinesin-1
light chain [35], caspases 3, 7 [57],
kinesin-1 heavy chain (unpublished
data)
⁄⁄Binding sites of Mek2 [55] and
Ubiquitin E3 ligase CHIP [56] have
not been mapped
(1) Speciﬁc expression in brain, especially
in the cerebellum and hippocampus
[30]
(2) Mutation in ATCAY gene leads to Cay-
man ataxia characterized by hypoto-
nia, mental dysfunction and
cerebellar ataxia [31]
(3) Promotes neuronal differentiation and
relocalises glutaminase to neurite ter-
minals and regulates glutamate pro-
duction [30]
(4) Transports mitochnodria on kinesin-1
[35]
(5) As an adaptor/scaffold for transporting
KGA on kinesin-1 along microtubules
of neurites (unpublished data)
(6) Binds E3 ligase CHIP and undergoes
polyubiquitination [56]
(7) As a presynapse substrate of caspases-
3 and -7. Contains 102-DETD-105
cleavage motif, releasing BCH frag-
ment that might regulate Mek2 sig-
naling [57]
(8) Interacts with Pin1 upon NGF stimula-
tion or stimulated by active Mek2;
Pin1 disrupts the binding between
BNIP-H and glutaminase [55]
(1) Intramolecular inhibition that is
released by NGF stimulation or active
Mek2 [55]
(2) Binding to CHIP (E3 ligase) and poly-
ubiquitination is likely for degrada-
tion [56]
Implicated in disease: Mutation in ATCAY
gene leads to Cayman ataxia [31] and is
also linked to the ‘‘jittery’’, ‘‘hesitant’’
and ‘‘sidewinder’’ ataxia models in mice
[46,47]
BNIP-XL (BNIP-2 Extra
Long; BMCC1-isoform 4)
Targets of BCH domain: RhoA
(strongest binding for T19N, F30L but
no binding to G14V and Q63L), RhoC
but not RhoB [18]; BCH domain
interacts with DH–PH domain of Lbc
RhoGEF and possibly p115RhoGEF
also [18]
Targets of other domain: Multiple
caspases [41]
Lbc binds to N-terminus and BCH
domain of BNIP-XL via its proline
region and DH–PH domains,
respectively [18]
(1) One of the 4 splicing variants encoded
by the BMCC1 gene (also known as
PRUNE2). BNIP-XL (BMCC1 isoform-
4) itself also undergoes alternative
splicing within BCH domain, generat-
ing BNIP-XLa and BNIP-XLb [18]
(2) Associated with neuronal apoptosis
and is expressed in brain, spinal cord
and dorsal root ganglia; predomi-
nantly in the neurons of the cranial
nerve motor nuclei and motor neurons
of the spinal cord [66]
(1) Alternative splicing encoded from the
BMCC1 locus; further splicing within
BCH domain generates BNIP-XLa and
BNIP-XLb
(2) BMCC1 expression is downregulated
after NGF-induced differentiation but
upregulated during the NGF-deple-
tion-induced apoptosis [66]
(3) Subjected to cleavage by caspases [41]
Implicated in disease:
(1) BMCC1-3 is a good prognosis marker
for neuroblastomas in children [66]
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Table 1 (continued)
Proteins Target proteins Functions Regulation
BMCC1/PRUNE2 binds GTP, 8-oxo-
GTP and putative protein targets
identiﬁed but not yet validated [69]
(3) BNIP-XL restricts binding of RhoA with
itsRhoGEFLbc, thusreducingRhoAacti-
vation and cellular transformation [18]
(4) Also binds to p115RhoGEF but the
function is unknown [18]
(5) Cleaved by caspases 3,6, 7, 8, 9 and 10
in vitro, or by caspases 8 and 9 in cells
[41]
(6) Binds GTP and 8-oxo-GTP and several
putative protein targets [69], and also
microtubule–associated protein,
MAP6 [93]
(2) BMCC1-1 is identiﬁed as a susceptibil-
ity gene for Alzheimer’s disease [71]
and BMCC1-2 as a biomarker for leio-
myosarcomas [72]
(3) BMCC1-3 and BNIP-XL (BMCC1-4) is
proapoptotic protein in neuronal cells
[66] and an antagonist of Rho-medi-
ated cellular transformation [18],
respectively
BNIP-S (BNIP-2 Similar;
BNIPL)
Targets of BCH domain: RhoA
(stronger preferences for T19N but no
binding to G14V) [33], Bcl2 [74],
BNIP-S [28], BNIP-2 [28], Cdc42GAP
[28,33,74], proto-Lbc RhoGEF [18]
⁄⁄Binding sites of the cell-
proliferation-related proteins MIF
and GFER have not been mapped [73]
(1) Induces apoptosis by targeting
Cdc42GAP and RhoA with its BCH
domain. This disrupts Cdc42GAP and
RhoA association thereby increasing
RhoA activation for cell rounding and
apoptosis [33]
(2) BCH domain of BNIPL-2 interacts with
Bcl2 and Cdc42GAP during apoptosis
[74]
(3) BNIPL-2 promotes invasion and
metastasis via Cdc42 activation and
upregulation of CD44 in human hepa-
tocellular carcinoma [75]
(1) Splicing variants, BNIP-Sa and BNIP-
Sb. BNIP-Sa induce cell rounding and
apoptosis whereas BNIP-Sb is local-
ized to the nucleus and has no effect
on cell morphology [28]
RhoGAP Family
Cdc42GAP
(p50RhoGAP;ARHGAP1)
Targets of BCH domain: RhoA [19],
Rab5 [89], Rab11 [89], BNIP-Sa
[28,33]
⁄⁄Binding sites of Nudel has not been
mapped [92]
(1) GAP for Cdc42 and Rho [77,81,83,85]
(2) BCH domain acts as a local modulator
to sequester RhoA from inactivation
by its adjacent RhoGAP domain [19]
(3) Target to endosome via BCH domain
and form complex with Rab11 and
Rab5 [89]
(4) Nudel sequesters Cdc42GAP at the
leading edge of the cell to increase
active Cdc42 in presence of phosphor-
ylated ERK [92]
(5) Promotes cell migration [81,82]
(6) Suppress muscle cell differentiation
by inactivating Cdc42 [34]
(1) Auto-inhibition [88]
(2) Sequestered by BNIP-Sa from inacti-
vating RhoA, leading to cell rounding
and caspase-independent apoptosis
[33]
Implicated in disease:
(1) Up-regulated in Waldenstrom macro-
globulinemia [79]
(2) Homozygous knockout embryo and
newborn mice have reduced organ
and body size, due to elevated JNK-
mediated apoptosis [81,83,84]
BPGAP1 (BCH containing,
proline-rich RhoGAP-
1;ARHGAP8)
Targets of BCH domain: RhoA, BNIP-2
BCH domain; K-Ras and SmgGDS
(unpublished data)
Targets of other domain: Cortactin
[36], Endophilin 2 [37], Pin1 [38],
Mek2 [38]
⁄⁄Binding sites of Cdc42 and Mek2
have not been mapped
(1) Induces membrane protrusions and
cell migration via interplay of BCH
domain, GAP domain and proline-rich
region [29]
(2) Induces motility by translocating
Cortactin to cell periphery [36]
(3) Induces EGFR endocytosis and ERK
activation by coupling to endophilin-
2 [37]
(4) BCH induces chronic K-Ras/Erk activa-
tion and PC12 neuronal differentiation
that is suppressed by another Rasmod-
ulator, SmgGDS (unpublished data)
(5) BNIP-2 promotes BPGAP1’s GAP activ-
ity towards RhoA and downregulates
cell proliferation (unpublished data)
(1) Splicing variants, BPGAP1–4 [29]
(2) Intramolecular inhibition at proline-
rich region, released by active Mek2
acting as scaffold to promote interac-
tion between Pin1 and BPGAP1 and
suppresses BPGAP1-induced cell
motility and ERK activation [38]
Implicated in disease: Upregulated in pri-
mary colorectal tumors [78] and cervical
cancer [80]
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conserved across different members, this Cdc42-binding motif for
BNIP-2 is only conserved in BNIP-XL and BNIP-H (Fig. 3C). How-
ever, no binding of Cdc42 have been observed for these two pro-
teins, indicating that unique structures surrounding this motif
could play an important role in the substrate recognition.
BNIP-2 utilizes another distinct motif 217-RRKMP-221 to medi-
ate its homophilic and heterophilic BCH/BCH interactions. The
homophilic interaction of BNIP-2 or its heterophilic binding with
Cdc42GAP could affect their ability to promote the inactivation of
Cdc42 in vitro, although such interactions do not affect their bind-
ing to Cdc42 [11]. Interestingly, such interaction as well as itsinteraction with Cdc42 are abrogated upon binding and phosphor-
ylated by FGF receptor [9]. Although the BCH domain of BNIP-2 ap-
pears insensitive towards either the GDP-bound or GTP-bound
form of Cdc42, its strong preference for the dominant negative
form of Cdc42–T17N and its near-complete loss of binding with
the constitutive active form, Cdc42–G12V [12] support the abso-
lute requirement of Gly-12 to promote their interaction, rather
than depending on the activity per se. The ability of BCH domains
to still recognize either active or inactive form of Cdc42 (and Rho in
other examples) appears to be consistent with its scaffold function
to bring any forms of GTPase and their immediate regulators in
context-dependent manner. The signiﬁcance of this recurring
AF
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Fig. 4. Functional plasticity and mechanisms of action by the BCH domains. BCH domains are involved in targeting small GTPases, their GAPs, GEFs, signaling receptors, cargo
enzymes or other cellular proteins to elicit diverse cellular responses. These are shown by the following models, depicted clockwise. (A) BNIP-2 induces extensive cell
elongation and membrane protrusions in single epithelial cells via the BCH domain binding to Cdc42 [32]. It also acts as a scaffold protein that couples the promyogenic
receptor, Cdo and activation of Cdc42 with the activation of p38a/b MAPK on the scaffold, JLP. The alliance of these two scaffold proteins promotes myogenic differentiation
[34]. (B) BNIP-H (or Caytaxin) promotes neurite outgrowth by engaging its BCH domain as a scaffold/adapter to trafﬁc and localize KGA (kidney-type glutaminase) towards
the neurites termini [30]. BNIP-H itself can be trafﬁcked by kinesin motor in hippocampus [35] supporting our observations that BNIP-H can act as an adaptor for
transportation of cargo proteins or signaling complexes along neurites (unpublished data). (C) BNIP-XL suppresses stress ﬁber formation and cellular transformation by
engaging its BCH domain to sequester RhoA from activation by RhoGEF, proto-Lbc; The N-terminal region of BNIP-XL interacts with the proline-rich region of Lbc. These
concerted interactions reduce the level of active RhoA, leading to disruption of stress ﬁbers and Lbc-induced cell transformation [18]. (D) BNIP-Sa induces cell retraction, cell
rounding and apoptosis, all via its BCH domain sequestering RhoA and also by displacing Cdc42GAP/p50RHoGAP from inactivating RhoA via its BCH/BCH interaction with
Cdc42GAP. Together, such mechanisms sequester RhoA from immediate inactivation by Cdc42GAP thereby facilitating the activation of RhoA, leading to cell rounding and
apoptosis [33]. (E) The BCH domain of Cdc42GAP sequesters RhoA from being inactivated by the adjacent RhoGAP domain, thus reducing GAP-mediated Rho inactivation and
preventing cell rounding [19]. (F) BPGAP1 enhances cell motility and ERK1/2 activation. The BCH domain of BPGAP1 induces short pseudopodia in MCF7 cells [29]. The
domain interplay of the BCH, PRR (proline-rich region; labelled P) and RhoGAP domains lead to enhanced cell motility and ERK1/2 activation. For example, through the PRR,
BPGAP1 mediates translocation of cortactin from cytosol to membrane periphery for cell migration [36] and it also engages EEN/Endophillin II to increase EGF receptor
endocytosis and ERK1/2 activation [37]. In addition, BPGAP1 can be negatively regulated by the peptidyl-prolyl cis/trans isomerase Pin1 via targeting both the PRR and the
RhoGAP of BPGAP1; thereby suppressing the BPGAP1-induced cell motility and ERK1/2 activation. Intriguingly, such interaction between BPGAP1 and Pin1 is promoted by the
active regulatory scaffold, Mek2 by aiding the relief of the auto-inhibited site in BPGAP1 [38].
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BNIP-S, BNIP-XL and Cdc42GAP.
Extending its involvement in anchoring membrane receptor sig-
naling, BNIP-2 has also been shown to play a crucial scaffold func-
tion to support Cdo receptor activation of Cdc42, in concert with
p38a/b-MAPK activation by another scaffold protein, JLP – all trig-
gered under the same Cdo receptor upon activation through N-cad-
herin ligation. This mechanism brings both scaffold proteins
together to activate myogenic differentiation [34,39]. Interestingly,
Cdo receptor binding sites have been mapped to encompass aa
261–292, which include the Cdc42-binding motif. The intricate
mechanism underlying the activation of Cdc42 by this Cdo-Bnip-
2-Cdc42 complex remains to be determined. Given the increasing
evidence that BCH domains can also interact with GEFs and GAPs,
it is tempted to speculate that either one such GEF is to be re-
cruited to activate the pathway, or/and a Cdc42GAP has been inac-
tivated. In the later scenario, overexpression of Cdc42GAP in the
same model system of C2C12 myoblasts suppressed the myogenic
differentiation. Through the same module of Cdo-Bnip-2-Cdc42,
BNIP-2 is also involved in promoting neuronal differentiation[40]. While providing one novel mechanism for speciﬁcity of
p38a/b activation during myogenic and neuronal differentiation,
forming scaffold alliances is becoming a distinctive mode of cell
surface receptor signaling.
Adding to its versatility, human BNIP-2 is subjected to cleav-
age by caspases 3, 6, 8, and 10 in vitro or at least by caspase 3, 8
and 9 inside the cells [41]. It can also be cleaved by granzyme B
[42]. All these processing occur outside the BCH domain of BNIP-
2. Granzyme B triggers apoptosis via the cleavage of a repertoire
of cellular proteins, leading to caspase activation and mitochon-
drial depolarization. As Granzyme B cleaved recombinant BNIP-2
in vitro and endogenous BNIP-2 was cleaved during the natural
killer cell-mediated killing of tumor cells [42] these observations
raise the possibilities that cleavage of BNIP-2 by caspases and
granzyme could lead to well controlled and timely release of
the potent pro-apoptotic BCH domains. However, the mechanism
by which BNIP-2 causes apoptosis remains unclear, although we
have shown that the corresponding BCH domain in BNIP-S lead
to apoptosis by activating through a caspase-independent but
Rho-dependent pathway [33]. As BNIP-2 harbors a Rho-binding
granzyme 
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Fig. 5. Linguistics of BCH domains. Schematic diagrams of (A) BNIP-2, (B) BNIP-H, (C) BNIP-XL with BMCC1-1/PRUNE2 and (D) BPGAP1, as the representative members of BCH
domain-containing proteins, highlighted with their known or putative functional motifs, including the Rho-binding domain, CRIB-like motif, BCH signature motif, BCH/BCH
interaction motif, caspase or granzyme cleavage sites and kinesin-targeting motifs. Note:  indicates the putative Rho binding domain based on close homology to known RBD
in BNIP-XL, BNIP-S and Cdc42GAP (see Fig. 3D) while  indicates putative Cdc42/Rac interactive binding domain based on close homology to known CRIB-like motif in BNIP-2
(see Fig. 3C). For BMCC1/PRUNE2, the sequence used is from accession number BAJ08045.1 [69].
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Cdc42GAP (Fig. 3A and D), the released fragment of BCH with
RBD might activate Rho towards apoptosis. Consistent with its
role in regulating apoptosis, expression of BNIP-2 mRNA has
been shown to be downregulated upon estrogen treatment, a re-
gime thought to confer neuroprotection against neurodegenera-
tive diseases such as Alzheimer’s disease [43]. Its expression is
also downregulated in the heart upon coxsackievirus B3 infec-
tion in mice [44], but up-regulated in lung cancers [45], further
indicating its complex nature of regulation in cell growth and
cell death. We have further observed that BNIP-2 retards MDCK
epithelial cells spreading and collective cell migration by activat-
ing Rho/ROCK/myosin signaling cascade (unpublished data)
whereas in ﬁbroblasts, BNIP-2 enhances the ability of BPGAP1to inactivate Rho, leading to greater loss of stress ﬁbers and reduced
cell proliferation (unpublished data). Taken together, these ﬁndings
support the notion that both BNIP-2 and BNIP-S are likely to act as
tumor suppressor instead of being proto-oncogenic.
To explore the multifunctional nature of BNIP-2, we recently
employed ﬂuorescent reporter construct coupled to Total Internal
Reﬂection Fluorescent (TIRF) microscopy that measured the activ-
ity of BNIP-2 especially its dynamics near the membrane. We ob-
served that BNIP-2 undergoes dynamics distribution between the
endosomes and cell protrusions along the microtubules, but with
major concentrations being detected at the protrusive tips. And,
this dynamics is recapitulated by the expression of the BCH do-
main alone (unpublished data). In this regard, the N-terminus of
BNIP-2 carries a putative kinesin-binding WED motif 94-
1 769600
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and B) that is required for its trafﬁcking inside the cells [35]. This
observation suggests that BNIP-2 could itself translocate towards
protrusive membranes to exert its scaffold functions there or it ac-
tively recruits and targets cargos (possibly signaling complexes) to
the right cellular compartments. The physiological signiﬁcance and
the mechanism of this function remain to be explored. Further-
more, it remains to be determined how alternatively spliced vari-
ants of BNIP-2 could be generated and regulated to impact on
any functions that have been described so far. Taken together,
BNIP-2 regulates diverse cellular functions by engaging multiple
partners and is likely to be activated under different cellular con-
text, pending on the biochemical signals and their impending tar-
get proteins.
2.2.2.2. BNIP-H (Caytaxin) with neuronal differentiation, neurotrans-
mission and ataxia. Unlike BNIP-2 which is ubiquitously expressed,
expression of BNIP-H (or Caytaxin) is highly speciﬁc to the brain,especially in the cerebellum and hippocampus [30]. Several forms
of mutations at the human and mouse BNIP-H loci have been
linked to a recessive congenital ataxia in human Cayman cerebellar
ataxia (thus named ‘‘Caytaxin’’) [31], and also linked to the ‘‘jit-
tery’’, ‘‘hesitant’’ and ‘‘sidewinder’’ ataxia models in mice [46,47].
This disease is associated with hypotonia, variable psychomotor
retardation, truncal ataxia and intention tremor, scoliosis, and ocu-
lar abnormalities. Interestingly, the two types of BNIP-H gene
mutation associated with Cayman ataxia were predicted to cause
point mutation (e.g. S310R) or truncation within the BCH domain
[31]. BNIP-H deﬁciency in rats also leads to generalized dystonia
[48], another neurologic movement disorder characterized by sus-
tained muscle contractions that produce abnormal movements or
postures. Furthermore, expression of BNIP-H is regulated in a
developmental and spatial-speciﬁc manner and present in presyn-
aptic cytosol [49] while its deﬁciency could disrupt signaling in
cerebellar cortex [50]. While all these genetics studies ﬁrmly
establish that BNIP-H is required for proper brain function, nothing
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at the molecular, cellular and physiological levels. To achieve this
objective, we employed proteomics/MALDI-TOF and identiﬁed a
kidney-type phosphate-activated glutaminase (KGA) as a binding
partner for BNIP-H. KGA is a metabolic enzyme responsible for
the production of the glutamate which can be used as a form of
neurotransmitter. We showed that BNIP-H expression is upregu-
lated in retinoic acid-induced neuronal differentiation in embry-
onic carcinoma cell P19 and BNIP-H could relocalise KGA to the
tips of neurons and control the steady-state level of glutamate
[30]. Our model suggests that deregulated level of glutamate in
BNIP-H-deﬁcient individuals could render glutamate excitotoxicity
or/and deregulated glutamatergic activation. This could then lead
to ataxia and dystonia and possibly other excitotoxicity-based neu-
ronal damage [51–54]. Subsequently, we have also identiﬁed sev-
eral more novel protein targets for BNIP-H, among them are the
heavy chain of kinesin-1 (previously named KIF5B) motor, Rab
small GTPases, Mek and Pin1 isomerase. We showed that nerve
growth factor stimulates the interaction of BNIP-H with pepti-
dyl–prolyl isomerase Pin1, a process reproduced by the presence
of a constitutive active form of Mek2 such that it involves the
release of an auto-inhibitory intramolecular interaction on
BNIP-H. Consequently, two binding sites for Pin1 and KGA have
been mapped and shown to be overlapping (Fig. 5B) such that
Pin1 disrupts the interaction between BNIP-H and KGA [55].
Interestingly, the mutation S310R found in a mutant form of
BNIP-H lies within one of the binding sites overlapping with those
of Pin1 and KGA. Its precise impacts on BNIP-H binding to all
known cellular partners still remain unclear.
BNIP-H has been shown to act as an adaptor to transport mito-
chondria on the kinesin-1 light chain along the neurites [35]. A
kinesin-binding motif (115-ELLEWED-120) has been identiﬁed.
How BNIP-H functions to transport KGA and regulated by differen-
tiation signals and whether there exist cargo proteins other than
KGA, all remain to be further investigated. Interestingly, unlike
BNIP-2 which targets Cdc42, BNIP-H interacts predominantly with
Rab GTPases and co-localized with them in endosomes and along
neurites, reﬂecting their tight regulation by vesicular-based trans-
port system (unpublished data). Furthermore, BNIP-H undergoes
polyubiquitylation by CHIP, a E3 ligase protein, probably for its
degradation [56]. Similar to BNIP-2 and BNIP-XL (see later),
BNIP-H is also subjected to cleavage by caspases. Interestingly,
BNIP-H is shown to be a presynapse substrate for caspase-3 and
caspase-7 that target the highly conserved 102-DETD-105 motif,
releasing the BCH domain that appears to regulate Mek2 signaling
through a yet unknown mechanism [57]. Since caspases activity is
essential for many other non-apoptotic functions in cell signaling,
learning and memory [58–60], differentiation of neural stem cells
[61], dendritic [62]/axon [63] pruning and cell migration [64,65],
it remains to be seen how these processes are linked to the control
of neuronal differentiation mediated by BNIP-H. As dysregulation
of BNIP-H function lead to cerebellar ataxia, dystonia, and possibly
other related neurological disorders, our current attempt to under-
stand the mechanistic function of BNIP-H and its checkpoints at
cellular and molecular levels could pave way to our future under-
standing on the neuronal remodeling, plasticity and neurotrans-
mission at synapses, and with a long term objective of
identifying key strategic target(s) for intervention in such diseases.
2.2.2.3. BNIP-XL with tumor suppression and neuronal differentia-
tion. BNIP-XL initially represents the longest form of the BNIP-2
family proteins, with its sequence homology extended beyond
the highly conserved BCH domain, hence we named it BNIP-2 Extra
Long [18]. To date, it is shown to be one of the four major isoforms
encoded via differential initiation sites from the complex BMCC1
gene (for BCH motif-containing molecule at the carboxyl terminalregion 1) located at the human chromosome 9 (9q21.2) [66–69].
This gene, spanning 295 kbp, is also known as PRUNE2 as it encodes
the largest isoform (BMCC1 isoform-1/BMCC1-1/PRUNE2-1/
NM_015225, 3088aa; or BAJ08045.1, 3062aa) that harbors a region
of homology with the PRUNE, a His-Asp-Asp super family proteins
at its N-terminus. It also harbors a coiled-coil region, a proline-rich
region and a putative P-loop sequence (Fig. 5C). A slightly shorter
isoform consisting of 3062aa may result from an alternative splic-
ing [69]. Interestingly, the Prostate Cancer Antigen 3 gene (PCA3), a
highly speciﬁc biomarker upregulated in prostate cancer, is located
within the intron 6 of BMCC1 but in the opposite orientation [67].
In contrast, BMCC1 isoform-2 (BMCC1-2/PRUNE2-2/C9orf65/
BC019095/NM_138818) comprises the ﬁrst 6 exons of BMCC1
but it terminates immediately upstream of the PCA3 gene. The iso-
form-3 (BMCC1-3/BMCC1/ABO50197; 2724aa) does not overlap
with BMCC1-2 but it comprises 13 distinct exons (exons 7–19)
positioned immediately downstream of PCA3 [66]. BNIP-XL is the
isoform-4 (BMCC1-4/KIAA0367/AY43213; 769aa) which has the
start site located still further downstream within the second exon
of BMCC1-3. All three isoforms-1, -3 and -4 encode the highly con-
served BCH protein domain. Interestingly, BNIP-XL mRNA itself can
undergo alternative RNA splicing, generating a 769 amino acid-
long protein (BNIP-XLa) and a 732 amino acid-long protein
(BNIP-XLb) (Fig. 2). The shorter variant results from alternative
splicing of exons 11 and 12 (with respect to exon numbering in
BNIP-XL), which introduces an in-frame stop codon. Multiple se-
quence analyses of BNIP-XL with BNIP-2, BNIP-Sa, BNIP-H/Cay-
taxin and BPGAP1 indicates the closest homology to BNIP-2
across the entire protein (58% identity, 74% similarity) whereas
its BCH domain is most similar to that of BNIP-H/Caytaxin (76%
identity, 90% similarity).
All isoforms of BMCC1 have been linked to, or identiﬁed as pos-
sible biomarker for, various human pathologies. For example,
BMCC1-1 was initially thought to offer an improved diagnosis for
prostate cancer because of its upregulation with PCA3 gene in pros-
tate cancers and in response to androgen [67]. However, both
genes may not appear to be tightly co-regulated [70]. BMCC1-1
has also been identiﬁed as a susceptibility gene for Alzheimer’s dis-
ease [71] while BMCC1-2 as a biomarker for leiomyosarcomas [72].
BMCC1-3 and BNIP-XL (BMCC1-4) have been shown to be a
proapoptotic protein in neuronal cells [66] and an antagonist of
Rho-mediated cellular transformation [18], respectively. Expres-
sion of BMCC1-3 enhances neuronal apoptosis upon NGF depletion
and is expressed in brain, spinal cord and dorsal root ganglia
(DRG). It also offers a good prognostic marker for childhood
neuroblastomas [66]. Overall, BMCC1-1 mRNA and proteins are
predominantly expressed in the neurons of the cranial nerve motor
nuclei and motor neurons of the spinal cord and to lesser extent, in
other nerve tissues [68,69]. DRG neurons express higher levels of
BMCC1-1 in their soma compared with adjacent cells. Moreover,
their expression is most profound in adult nerve tissues than those
in fetal or neonatal nerve tissues.
These expression proﬁles suggest that various BMCC1 isoforms,
including BNIP-XL, may contribute to the maintenance of mature
nervous systems and inhibition of unwarranted cell growth and
proliferation. However, the underlying mechanisms for their action
remain unknown. In contrast to the positive regulation of BNIP-2
and BNIP-S on their cognate GTPases inside the cells, i.e. activating
Cdc42 and RhoA, respectively, BNIP-XL affects actin cytoskeletal
reorganization and suppresses cellular transformation by inhibit-
ing Rho signaling instead [18]. At the molecular levels, the BCH do-
main of BNIP-XL interacts with RhoA and RhoC but not with RhoB.
Furthermore, it binds to speciﬁc conformers of RhoA and also
mediates association with the catalytic DH–PH domains of Lbc, a
RhoA-speciﬁc guanine nucleotide exchange factor (RhoGEF). Con-
sistent with the observations made by other members, BNIP-XL
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of RhoA but it targets the fast-cycling F30L and the dominant-neg-
ative T19N mutants. Whereas overexpression of BNIP-XL reduces
active RhoA levels without changing its level of expression, knock-
down of BNIP-XL expression has the reverse effect. The constitutive
active G14V and Q63L are locked in an active conformation mim-
icking GTP-RhoA in vitro, because residues for GAP recognition in
the P-loop (residues 12–19) and switch II (residues 62–68) regions
have been mutated. By contrast, the ‘fast-cycling’ F30L is spontane-
ously active and demonstrates enhanced GDP to GTP exchange,
while retaining regular GTP hydrolysis rates catalyzed by GAPs.
The dominant negative T19N mutant on the other hand, sequesters
and inhibits multiple endogenous RhoGEFs, preventing RhoA acti-
vation leading to elevated GDP-RhoA levels in vivo. Collectively,
these results suggest that BNIP-XL inhibits distinct RhoA pathways,
including stress ﬁber assembly and transformation. Such result is
consistent with its function as an antagonist for cell growth in
ﬁbroblasts or as a pro-apoptotic factor in neuronal cells. Further
mutagenesis studies revealed that BNIP-XL utilizes both its BCH
domain and the N-terminus to target the DH–PH moiety and the
proline-rich region of Lbc, respectively [18]. Consequently, BNIP-
XL inhibits Lbc-induced oncogenic transformation. Given the
importance of RhoA and RhoGEF signaling in tumorigenesis,
BNIP-XL could suppress cellular transformation by preventing sus-
tained Rho activation in concert with restricting RhoA and Lbc
binding via its BCH domain. This could provide a general mecha-
nism for regulating RhoGEFs and their target GTPases. The identi-
ﬁcation of a speciﬁc BNIP-XL mutant that uncouples GEF
interactions while retaining RhoA binding should address the spe-
ciﬁc contributions of BNIP-XL in linking actin cytoskeleton rear-
rangements and oncogenic transformation. Interestingly, some
BMCC1 isoforms have been shown to bind GTP, its oxidized form
8-oxo-GTP (an agent known to cause mutagenesis and cell death),
the T-cell activation RhoGAP, TAGAP [69] and microtubule–associ-
ated protein MAP6 [93]. While their mechanism of binding and
function remain to be established, these observations imply a com-
plex regulatory scaffold function by BNIP-XL and possibly other
BMCC1 isoforms in regulating GTPase signaling and other cell
growth/death signaling pathways. Adding to the dynamic roles of
these proteins in neuronal cell growth and development, BNIP-
XL, similar to BNIP-2 and BNIP-H, can also undergo cleavage by
multiple caspases-3, 6, 7, 8, 9 and 10 in vitro and at least by casp-
ases 8 and 9 inside the cells, albeit at site distinct from that of
BNIP-2 [41] (Fig. 5C). Such actions could result in the release of
the BCH domain or its smaller fragments that are crucial in regulat-
ing apoptosis or engaging small GTPases signaling in cell dynamics
control. Surprisingly, unlike BNIP-2, BNIP-H and BNIP-S which all
carry a highly conserved ‘‘E(L/F)EWED’’ kinesin-1 light chain bind-
ing motif, BNIP-XL do not posses such a motif. Instead, a similar
motif ‘‘DLDWDD’’ is found in its longer isoform BMCC1-1/PRUNE2
(aa 1139–1144) and BMCC1-3 (aa 777–782; [35]), which are lo-
cated outside the region of homology to the BNIP-2 Family proteins
(Fig. 5C). It remains to be seen whether BNIP-XL trafﬁcs in the cell
via other motor system or it could ‘‘piggyback’’ on these longer iso-
forms via their BCH/BCH interaction motif.
2.2.2.4. BNIP-S with apoptosis. Comparing the functions of BNIP-2,
BNIP-H and BNIP-XL, BNIP-S (or BNIPL for BNIP-2-Like) represents
the most potent form of pro-apoptotic BCH containing protein de-
spite sharing high sequence homology (86% similarity) with the
BCH domain of BNIP-2 or 72% similar across the whole protein
[28]. Phylogenetic analyses suggest that BNIP-S could have ap-
peared earlier than the others during the evolution [26]. BNIP-S
can undergo alternative RNA splicing with the retention of an in-
tron that introduces a non-sense mutation. This results in a trun-
cated variant, BNIP-Sb, that is devoid of the last 71 amino acidsof the BCH domain. Full-length BNIP-S is present in the cytosol
and its overexpression cause extensive cell rounding, leading to
caspase-independent apoptosis. However, BNIP-Sb is localized to
the nucleus and fail to exert any changes in cell morphologies or
cell fates [28]. The transcripts for both variants can be detected
in different cancer lines. It appears that the expression for the
full-length version is more abundant in the male reproductive or-
gan of mice [28], or in the human placenta and lung [73]. Most sig-
niﬁcantly, this apoptotic effect is induced by the BCH domain
which triggers an initial phase of extension followed by extensive
retraction. And this effect can only be blocked by co-expressing
dominant negative mutant form of RhoA, indicating that this
induction is likely to involve activation of Rho [33]. BNIP-S does
not bind Rac1 or Cdc42. However, BNIP-S BCH domain binds to
the unloaded or GDP-bound form of RhoA but not to the GTP-
bound RhoA. And when co-expressed inside the cells, BNIP-S inter-
acts strongly with the dominant negative mutant of RhoA, T19N,
but not with the constitutively active RhoA-G14V [33]. Sequence
comparison between its BCH domain and REM Class 1 Rho-binding
domains reveals a putative RBD-like motif which when deleted
lead to the loss of RhoA binding and failure to execute apoptosis.
All these observations indicate that BNIP-S binds to inactive
RhoA and that could lead to its activation, leading to cell rounding
and apoptosis. Interestingly, unlike BNIP-2 which uses the same
BCH/BCH binding motif ‘‘RRKMP’’ for its both homophilic and het-
erophilic interaction with BCH domains, BNIP-S does not possess
such motif. Instead, it uses a separate motif 215-ATWYVKA-221
for its homophilic BCH/BCH interaction [33] (Fig. 3A), and this
interaction is required for its apoptotic activity [28]. The binding
site for Cdc42GAP is instead located at the region proximal to the
BCH domain (aa 133–147), overlapping part of the extended Rho-
binding region of the BCH domain. Consequently, overexpression
of BNIP-S can capture RhoA for further activation while separate
pools of BNIP-S sequester Cdc42GAP via their heterophilic interac-
tion. Acting in concert, this mechanism leads to RhoA activation,
cell rounding and apoptosis (Fig. 4D). However, it remains to be
seen how BNIP-S binding to RhoA could lead to activation of RhoA
in the absence of negative regulation by Cdc42GAP. Perhaps, BNIP-
S could recruit a RhoGEF in their close proximity since dominant
negative mutant of RhoA could inhibit the pro-apoptotic effect of
BNIP-S. In this regard, BNIP-S has been shown to interact with pro-
to-Lbc RhoGEF [18] but it remains to be conﬁrmed by means of ge-
netic knockdown and mutant studies to see if this binding is
speciﬁc and linked to this process.
In addition to involvement of Rho signaling in its pro-apoptotic
effect, BNIP-S has also been shown to interact with two cell-prolif-
eration related proteins, MIF (macrophage migration inhibitory
factor) and GFER (growth factor erv1 (Saccharomyces cerevisiae)-
like) and help suppress colony formation and cell proliferation
[73]. Another variant of BNIP-S (BNIPL-2), also interacts with Bcl-
2 and Cdc42GAP via its BCH domain [74]. Similar to the proposed
function of BNIP-2, BNIPL-2 is thought to suppress the anti-apopto-
tic effects of Bcl2 and the activity of Cdc42GAP towards Cdc42. Fur-
thermore, BNIPL-2 can also promote invasion and metastasis via
Cdc42 activation and upregulation of CD44 in human hepatocellu-
lar caricinoma [75]. However, none of these studies had completely
delineated their curical binding sites on the BCH domains in order
to establish their molecular interaction and functional relationship.
2.2.2.5. Cdc42GAP and BPGAP1 with cell morphogenesis, migration,
invasion and neuronal differentiation. RhoGAPs function as negative
regulators by activating the intrinsic Rho GTPase activity, convert-
ing their active GTP-bound state to the inactive GDP-bound state.
The human genome encodes more than 80 RhoGAPs with distinc-
tive arrays of protein domain/motifs and exerts diverse physiolog-
ical outcomes [76]. These domain/motifs could potentially act as
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connecting to various signaling networks via protein–protein
interactions. The Cdc42GAP (p50RhoGAP or ARHGAP1; [77]) and
its homolog BPGAP1 (or ARHGAP8; [29,78]) are two BCH do-
main-containing RhoGAPs (Fig. 2) that functions biochemically as
a GAP for Cdc42 and Rho. Expression of Cdc42GAP is up-regulated
in Waldenstrom Macroglobulinemia [79] whereas expression of
BPGAP1 is elevated in primary colorectal tumors [78] and cervical
cancer [80]. However, the molecular bases and cellular outcomes
for their elevated expression remain unclear. The Cdc42GAP regu-
lates diverse functions, including cell migration [81,82] and muscle
cell differentiation by inactivating Cdc42 [34]. Its homozygous
knockout embryos/new born mice displayed reduced organ and
body size, owing to increased spontaneous JNK-mediated apopto-
sis [81,83,84]. Although the biochemical and structural properties
of the GAP domain of Cdc42GAP are already well deﬁned [77,85–
87], little is known on how their GAP functions inside the cells
are regulated. In particular, the impact of the BCH domain that is
located N-terminus proximal to the GAP domain remains largely
undetermined.
We recently showed that the BCH domain on Cdc42GAP could
serves as a local modulator to sequester RhoA from being inacti-
vated by its adjacent GAP domain ([19]; Fig. 4E). This BCH domain
cannot distinguish between the GDP-bound and GTP-bound form
of RhoA. Further mutagenesis revealed a novel RhoA-binding motif
(residues 85–120) within the BCH domain (Fig. 3A and D). Deletion
of this motif signiﬁcantly reduced BCH inhibition on GAP-mediated
cell rounding in human cervical epithelial cells, whereas its full
suppression also required an intramolecular interaction motif (res-
idues 169–197).
Activation of RhoA can lead to distinct cellular and physiological
outcomes, depending on the cell types and the environment they
are in, the types of processes (e.g. cell spreading, cell adhesion ver-
sus cell motility) and the involvement of different constituent pro-
teins such as upstream regulators or downstream effectors that
propagate the signals at different locales and timing. Cdc42GAP
expression (hence inactivation of Rho) would lead to cell protru-
sion in epithelial breast cancer MCF7 cells. When BNIP-S is overex-
pressed, this protein induces cell rounding and apoptosis by
displacing Cdc42GAP from inactivating RhoA. Separate pools of
BNIP-S would then bind RhoA and that lead to RhoA activation pos-
sibly by engaging a RhoGEF. It is likely that, while preventing RhoA
from being inactivated by the GAP domain of Cdc42GAP, formation
of BNIP-S/RhoA complex could trigger additional signaling path-
way(s) that couples the activation of Rho to apoptosis. In contrast,
when Cdc42GAP is expressed in cervical epithelial HeLa cells, this
protein posseses minimal GAP activity towards RhoA owing to
sequestration of RhoA by the adjacent BCH domain in cis [19],
hence RhoA is not inactivated and HeLa cells remain cuboidal.
However, when this sequestration is lost (evidenced by deleting
the RhoA-binding motif in the BCH domain), the GAP will inacti-
vate Rho. Under this condition, inactivation of Rho leads to collapse
of stress ﬁbers and cell adhesion, and cells become rounded up in-
stead of rendering protrusion. These observations therefore high-
light the plasticity and contextual signaling of Rho on cell
morphogenesis under the inﬂuence of BCH domains.
Recent studies also showed that the BCH domain undergoes
autoinhibition in vitro [88] and is required for its endosomal local-
ization and binding to Rab5 and Rab11 [89]. Interestingly, the other
plant RhoGAPs commonly referred to as RopGAPs (Rop, Rho of
plants) are associated with a Cdc42/Rac interactive binding (CRIB)
motif at their N-terminus [90]. This CRIB motif can help regulate
the local GAP activity by forming high afﬁnity complexes with spe-
ciﬁc Rho proteins and GAP domains and acts as lid for binding and
releasing Rho of plants [91]. Such a sequestration of substrate in cis
by the tandem Rho-binding domains therefore provides a novelmechanism for regulating the local activity of Cdc42GAP towards
Rho. This mechanism could have important bearings on previously
unappreciated function of BCH domains or the ‘‘BCH-like’’ CRAL–
TRIO domains in other RhoGAPs or RhoGEFs. In a mechanism sim-
ilar to the activation of RhoA by BNIP-S which blocks Cdc42GAP
from acting on Rho through their heterophilic BCH/BCH binding
[33], the function of Cdc42GAP can also be suppressed at the lead-
ing edge of cells through its sequestration by Nudel, a cytoplasmic
regulator for dynein that is activated by active Erk [92]. Conse-
quently, more Cdc42 is activated.
In comparison, we have identiﬁed BPGAP1 (or ARHGAP8), a
close homolog of Cdc42GAP, and showed that it activates cell pro-
trusions and cell migration via the interplay of its BCH domain, a
proline-rich region (PRR) and a GAP domain [29]. At least 4 alter-
native RNA splicing variants have been described, including those
present in the BCH domain (Fig. 2), thus adding to the versatility
and functional diversity in the BPGAP family proteins [29]. Specif-
ically, the BCH domain of BPGAP1 induces Cdc42/Rac-dependent
membrane protrusions that are necessary for its physical and func-
tional coupling to cortactin and endophilin-2 which bind to its pro-
line-rich region (PRR). Cortactin helps form branching actin
network [36] whereas endophilin-2 promotes EGF receptor endo-
cytosis for enhanced ERK signaling [37]. This process is also aug-
mented by the activity of the RhoGAP domain that inactivates
Rho. Furthermore, we showed that active Mek2 stimulates the re-
lease of an auto inhibition on the PRR, thus promoting binding of
the peptidyl–prolyl isomerase Pin1 to the PRR and the RhoGAP do-
main to suppress BPGAP1-induced acute Erk activation and cell
motility (Figs. 4F and 5D; [38]). Interestingly, such mechanism is
also employed by the BCH domain of BNIP-H where Mek2 pro-
motes Pin1 binding and disruption of the binding of its cargo, glu-
taminase KGA [55]. It remains to be investigated whether this
mechanism would affect the versatility of the BCH domain in
BPGAP1.
We had earlier reported on the role of BCH domain in stimulat-
ing ERK signaling, through a yet unknown mechanism [37]. Using
proteomics pulldown and candidate approaches, we have since
identiﬁed several novel partners, including Ras and one of its reg-
ulators, SmgGDS. We show that BCH domain binds to K-Ras and
that leads to enhanced Ras/ERK signaling necessary for the neurite
outgrowth and differentiation. Knockdown of SmgGDS potentiates
K-Ras/BCH-mediated Erk activation further, revealing a novel tri-
partite regulation of Ras/Erk by the BCH domain (unpublished
data). And through its heterophilic BCH/BCH interaction of BNIP-
2, we are examining how BNIP-2 and BPGAP1 would co-regulate
Rho, Ras and Cdc42 signaling.3. Conclusions and future perspective
Protein domains evolve to change their biochemical and bio-
physical properties to confer different roles in recognizing either
speciﬁc or diverse targets and to function at unique or multiple lo-
cales. They usually do not work in isolation but they interact with
other molecule(s) that carry the same or with distinct protein
modules or other non-peptide ligands – all deﬁned by their unique
sequence motifs. Many domains also co-exist by various copy
numbers and permutation in one particular protein. Such designs
help thrive for their optimal signaling capabilities, forming more
sophisticated yet well coordinated network of signaling hubs.
The properties and functions of these domains can also be modiﬁed
by biochemical and mechanical signals which cells receive from
the external environments. Therefore, optimal design and engi-
neering of domain architecture equipped with single or multiple
motifs allow them to execute as well as receiving feedback for bet-
ter integration of cell signaling.
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quired many of these key features that enable them function as
versatile regulatory scaffold modules. Through their multiple func-
tional motifs, some of which obvious but some are cryptic, they
interact with a broad spectrum of targets, ranging from membrane
receptors, different GTPases and their immediate regulators such
as GEFs and GAPs, kinase such as Mek2, isomerase Pin1, anti-apop-
tosis protein Bcl2 and key metabolic enzymes such as glutaminase,
impacting ultimately on cell growth, apoptosis, morphogenesis,
migration, metabolism and differentiation. While all these obser-
vations point to the functional plasticity of BCH domains and fur-
ther underscore the importance of BNIP-2 family and BPGAP
family proteins in cell dynamics and cell fates control, the precise
mechanisms underlying these dynamic processes and their physi-
ological impacts remain to be further elucidated. Here, we reﬂect
on several interconnected issues related to the structural, func-
tional, mechanical, evolutionary, physiological aspects of BCH do-
mains and the cellular environments these proteins are exposed
to, and aim to understand them at the molecular, cellular and tis-
sue levels (Fig. 6). Some of these are summarized below:
(1) What are the structural bases underlying the plasticity ver-
sus speciﬁcity of BCH domains in recognizing multiple and
diverse targets? In particular, within the same class of part-
ner, such as Rho, how do they distinguish between the active
G14V which they do not bind versus inactive mutant T19N
which they bind best, despite that the same BCH domain
binds both GDP-bound and GTP-bound form of Rho equally
well? What are the atomic and molecular bases that distin-
guish BCH domain from other conventional GTPase-bindingSp
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Fig. 6. Future perspective: elucidating the functional plasticity of BCH scaffold protein do
molecular and cellular bases for the physiological functions and regulation by the BCH do
target proteins including those that confer unique GTPase-binding proﬁle (e.g. Rho, Cdc4
mutant T17N is most preferred but constitutive G12V is the least or no binding) and the
between cell growth, proliferation, differentiation regimes (e.g. receptor tyrosine kinase
inﬂuence of biochemical or/and mechanical cues such as substrate rigidity; (iii) examinin
cell migration; (iv) deciphering their post-translational protein modiﬁcations (via phosp
identiﬁcation of cargo proteins such as metabolic enzymes and signaling complexes; (v) e
exploring the signiﬁcance of alternative RNA splicing variants in physiological and horm
transcription, micro-RNA and translation, and (viii) elucidating their distinct roles in
systematically examined and their precise functions/steps elucidated. For clarity, the mod
domains (orientation is hypothetical) while each could still act as distinctive scaffold mod
GAPs ( sign).domains of GEFs, GAPs and GDIs? Do other BCH-like
domains also possess some of the binding properties such
as GTPase binding? This is of special interest, as the CRAL–
TRIO domains present in the RasGAP (e.g. NF1) and RhoGEF
(e.g. Trio, DBS) could indeed engage some of these GTPases
to regulate cell morphogenesis, migration, apoptosis and dif-
ferentiation. Identiﬁcation and systematic studies of other
BCH-domain-containing proteins will also help to provide
further insights into the mechanistic functions of this
emerging class of protein module.
(2) How are signaling pathways connected by their binding to
BCH domains? Are these pathways merely operating in par-
allel by different pools of BCH domain proteins or are they
physiologically or physically linked? To date, we have
observed the signiﬁcant impact of BCH domains either
directly or indirectly via other domains they are associated
with, on various signaling nodes, especially in the FGF and
Cdo receptor signaling, various Rho, Ras, Rab GTPases, some
kinase, isomerase, caspases, Bcl2 and even the metabolic
pathway. Under what conditions are they functionally
linked? And given that some BCH domains are already tar-
gets of kinases, ligase and isomerase, what are the signals
that modify their properties through phosphorylation, ubiq-
uitination and isomerization and what are the impacts on
their functions?
(3) What are the dynamic features of BCH domains that help
them achieve their multifunctional roles? And how are these
functions regulated in space and time at the cellular to tis-
sue/organismal levels. For examples, BNIP-H and BNIP-2
are actively transported along the microtubules during neu-Cytoskeletal 
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mains across molecular, cellular and physiological levels. To further understand the
mains, future works will aim at (i) solving the structures of BCH domains with their
2, Ras, Rab) and their dependence on speciﬁc conformation (e.g. dominant negative
BCH/BCH interactions; (ii) exploring their diverse and dynamic signaling crosstalk
s, GTPases, p38 and Erk) and key metabolic pathways (e.g. glutaminase) under the
g their roles on actin and microtubule dynamics, leading to cell morphogenesis and
horylation, ubiquitination and isomerization) and intracellular trafﬁcking as well as
xamining their possible binding and regulation by lipids and phosphoinositides; (vi)
onal regulation; (vii) identifying their modes of gene regulation and expression by
tissue/organogenesis using various vertebrate models. All these issues will be
el presented here depicts the complex between BNIP-2 and Cdc42GAP via their BCH
ule to regulate binding and activity of 3G-Signalome, i.e. GTPases, GEFs (+ sign) and
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and delivering any cargos or are they being recruited to
the neurites tips before exerting their scaffold functions
there? What are those cargos? Are they metabolic enzymes
or signaling complexes? Moreover, with their ability to rec-
ognize multiple GTPases on the same domains, e.g. via their
tandem RBD-like and CRIB-like motifs present in BNIP-2 BCH
domain, it is tempted to speculate that this BCH domain can
also regulate Rho in addition to Cdc42 signaling. If so, what
are the consequences on the spatial and temporal activities
of these GTPases?
(4) As cells sense both biochemical and mechanical cues under
various conditions, it will be important to address whether
function(s) of BCH domains, that is usually linked to receptor
and Rho signaling, is itself subjected to both the biochemical
and mechanical triggers. And, how those signals inﬂuence
the dynamic distribution of BCH domain proteins and their
ability to regulate the actin and microtubule network associ-
ated with extensive morphogenesis and motility.
(5) Are BCH domains certiﬁed ‘‘lipid-free?’’ Despite relatively
low sequence identity between the BCH domain and
CRAL–TRIO and other lipids binding domains, several studies
including ours have not excluded entirely the ability of BCH
domain to recognize certain lipids for their function or reg-
ulation. It is still plausible that certain species of lipids
including the phosphoinositides, could act as ligands to help
regulate functions of the BCH domains instead of serving as
the substrates for transportation. However, the authenticity
of their binding would require further conﬁrmation in vivo
or cell-based system.
(6) As BCH domains confer functional diversity, the proteins and
the genes from which they are encoded are expected to be
under tight physiological regulation. This could take in the
forms of gene transcription, protein expression and stability,
and of course their ability to undergo alternative RNA splic-
ing. The unique pattern of RNA splicing, as we frequently
observe in BNIP-2, BNIP-S, BNIP-XL and BPGAP1 calls for
attention on their changes in the splicing pattern in response
to hormonal and stress signals. Similarly, their regulation by
microRNA and tissue speciﬁcity factors should also be exam-
ined in the right context of cell signaling;
(7) Last but not least, as functionalities and plasticity of BCH
domain containing proteins are being examined, we should
consider developing various vertebrate models to mimic
and interrogate the actual physiological response associated
with the signaling pathways. These model systems of mice
to zebraﬁsh allow us establish necessary platforms to detect
their impacts on developmental processes as well as for drug
screening. Coupled with genetic manipulations of knock-
down and functional rescues with pathway/partner-speciﬁc
mutants in the cell culture and knockout/knockdown or
knock-in for the in vivo models system, can we clearly deci-
pher some of the true meaning behind the multiplexing
roles of BCH domain containing proteins.
With the advent of high- and super-resolution live microscopy
and the availability of relevant biosensors for signaling proteins,
one could trace the spatiotemporal dynamics of BCH domain con-
taining proteins or the BCH domains alone and their physical local-
ization with their partners under different cellular contexts and
genetic backgrounds. And with various biophysical and structural
determination tools such as NMR to map conformational shifts
and X-ray crystallography for detailed binding sites, one can start
generating more precise mutants to interrogate their functional
plasticity and dynamics distribution in the cells and in tissues.
Such versatile properties not only underlie their central roles incontrolling normal physiology but they also offer us exciting pros-
pects of exploiting them as potential targets of therapeutic inter-
vention. Furthermore, it is plausible now to think about creating
novel cellular processes and functions by re-wiring speciﬁc net-
works or modifying their responses using synthetic scaffold pro-
teins. It is with these motivations that we should continue to
deﬁne the form (structure), the meaning (interactomes) and the
context (when, where and regulation) of such linguistic designs
of BCH domains that their functional plasticity and biological sig-
niﬁcance can be fully appreciated.
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